We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-7.50 | -0.44% | 1,697.50 | 1,697.50 | 1,698.50 | 1,711.00 | 1,695.50 | 1,705.00 | 452,037 | 09:03:44 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.22 | 70.07B |
TIDMGSK
RNS Number : 5180D
GlaxoSmithKline PLC
19 February 2020
GlaxoSmithKline plc (the ' Company ')
Vesting of Performance Share Plan Awards
This notification sets out the vesting details of awards over Ordinary Shares and American Depositary Shares ('ADSs') made to Persons Discharging Managerial Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') in 2017 under the GlaxoSmithKline 2017 Performance Share Plan ('PSP'), which were subject to relevant business performance conditions. Awards were made in 2017 following the approval of the 2017 Remuneration Policy and the 2017 PSP rules by shareholders at the Annual General Meeting in May 2017. The three-year performance period for the 2017 awards commenced on 1 January 2017 and ended on 31 December 2019.
The Remuneration Committee determined that the normal three-year vesting period for the award made to the Chief Executive Officer should end in July 2020 on the third anniversary of the award, and thereafter the additional two-year vesting period applicable to Executive Directors would apply to her award. For all other Corporate Executive Team members and PSP participants who received the 2017 awards, the awards vested on 17 February 2020 (for awards over Ordinary Shares) and 18 February 2020 (for awards over ADSs), following the determination of performance and to meet tax compliance requirements in some markets.
The performance measure vesting details for those PDMRs who received awards in 2017 are set out in the following table.
Outcome and Vesting Level Portion Measure and Outcome % of maximum % of award of the Award ------------------------------------------- ------------- ----------- Adjusted Free Cash Flow - For the three-year period, the Company achieved Adjusted Free Cash Flow calculated in accordance with the principles for the measure of GBP13bn, which is above the level of GBP12.95bn required for maximum vesting. Adjustments to the original target and vesting schedule were communicated 1/3rd in the 2018 Annual Report. 100 33.333 ------------------------------------------- ------------- ----------- Total Shareholder Return - For the three years ending 31 December 2019, the Company's Total Shareholder Return ranked 8th, which is below the threshold vesting level against a comparator group of 10 global pharmaceutical 1/3rd companies including GSK. 0 0 ------------------------------------------- ------------- ----------- R&D New Products - For the three-year period, the Company achieved New Product sales calculated in accordance with the principles for the measure of GBP7.254bn, which is above the level of GBP5.099bn required for maximum vesting. The threshold vesting 1/3rd level was GBP4.172bn. 100 33.333 ------------------------------------------- ------------- ----------- Total vesting for 2017 award 66.666% Lapsed 33.334% -------------------------------------------------------------------- -----------
The notifications that follow are for awards made to PDMRs and detail the PSP conditional awards that vested, including dividends accrued, on 17 and 18 February 2020. The balance of the award made to each PDMR has lapsed.
The closing prices of Ordinary Shares and of ADSs of GlaxoSmithKline plc on their respective vesting dates were GBP16.616 and $43.55.
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA') ==== =========================================================================================== a) Name Mr R Connor ==== ======================================== ================================================= b) Position/status President, Global Vaccines ==== ======================================== ================================================= c) Initial notification/ Initial notification amendment ==== ======================================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== =========================================================================================== a) Name GlaxoSmithKline plc ==== ======================================== ================================================= b) LEI 5493000HZTVUYLO1D793 ==== ======================================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== =========================================================================================== a) Description of Ordinary Shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 ==== ======================================== ================================================= b) Nature of the The number of Ordinary Shares vesting on transaction awards granted in 2017 under the Company's 2017 Performance Share Plan. ==== ======================================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ==== ======================================== ===================== ======================= GBP0.00 93,106 =================================================================== ======================= d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ================================================================ ============================== e) Date of the transaction 2020-02-17 ==== ======================================== ================================================= f) Place of the N/A transaction ==== ======================================== ================================================= 1. Details of PDMR/person closely associated with them ('PCA') ==== =========================================================================================== a) Name Ms D Conrad ==== ======================================== ================================================= b) Position/status SVP, Human Resources ==== ======================================== ================================================= c) Initial notification/ Initial notification amendment ==== ======================================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== =========================================================================================== a) Name GlaxoSmithKline plc ==== ======================================== ================================================= b) LEI 5493000HZTVUYLO1D793 ==== ======================================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== =========================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 ==== ======================================== ================================================= b) Nature of the The number of Ordinary Shares vesting on transaction awards granted in 2017 under the Company's 2017 Performance Share Plan. ==== ======================================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ==== ======================================== ===================== ======================= GBP0.00 9,168 =================================================================== ======================= d) Aggregated information N/A (single transaction) ==== Aggregated volume Price
================================================================ ============================== e) Date of the transaction 2020-02-17 ==== ======================================== ================================================= f) Place of the N/A transaction ==== ======================================== ================================================= 1. Details of PDMR/person closely associated with them ('PCA') ==== ============================================================================================ a) Name Mr J Ford ==== ======================================== ================================================== b) Position/status SVP & General Counsel ==== ======================================== ================================================== c) Initial notification/ Initial notification amendment ==== ======================================== ================================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== ============================================================================================ a) Name GlaxoSmithKline plc ==== ======================================== ================================================== b) LEI 5493000HZTVUYLO1D793 ==== ======================================== ================================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== ============================================================================================ a) Description of American Depositary Shares ('ADSs') the financial instrument ISIN: US37733W1053 ==== ======================================== ================================================== b) Nature of the The number of ADSs vesting on awards granted transaction in 2017 under the Company's 2017 Performance Share Plan. ==== ======================================== ================================================== c) Price(s) and Price(s) Volume(s) volume(s) ==== ======================================== ===================== ======================== $0.00 5,221 ===================== ======================== d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ========================================= ====================================================== e) Date of the transaction 2020-02-18 ==== ======================================== ================================================== f) Place of the N/A transaction ==== ======================================== ================================================== 1. Details of PDMR/person closely associated with them ('PCA') ==== =========================================================================================== a) Name Mr N Hirons ==== ======================================== ================================================= b) Position/status SVP, Global Ethics and Compliance ==== ======================================== ================================================= c) Initial notification/ Initial notification amendment ==== ======================================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== =========================================================================================== a) Name GlaxoSmithKline plc ==== ======================================== ================================================= b) LEI 5493000HZTVUYLO1D793 ==== ======================================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== =========================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 ==== ======================================== ================================================= b) Nature of the The number of Ordinary Shares vesting on transaction awards granted in 2017 under the Company's 2017 Performance Share Plan. ==== ======================================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ==== ======================================== ===================== ======================= GBP0.00 34,302 =================================================================== ======================= d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ================================================================ ============================== e) Date of the transaction 2020-02-17 ==== ======================================== ================================================= f) Place of the N/A transaction ==== ======================================== ================================================= 1. Details of PDMR/person closely associated with them ('PCA') ==== =========================================================================================== a) Name Ms S Jackson ==== ======================================== ================================================= b) Position/status SVP, Global Communications & CEO Office ==== ======================================== ================================================= c) Initial notification/ Initial notification amendment ==== ======================================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== =========================================================================================== a) Name GlaxoSmithKline plc ==== ======================================== ================================================= b) LEI 5493000HZTVUYLO1D793 ==== ======================================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== =========================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 ==== ======================================== ================================================= b) Nature of the The number of Ordinary Shares vesting on transaction awards granted in 2017 under the Company's 2017 Performance Share Plan. ==== ======================================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ==== ======================================== ===================== ======================= GBP0.00 9,168 =================================================================== ======================= d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ================================================================ ============================== e) Date of the transaction 2020-02-17 ==== ======================================== ================================================= f) Place of the N/A transaction ==== ======================================== ================================================= 1. Details of PDMR/person closely associated with them ('PCA')
==== =============================================================================================== a) Name Mr D Jackson ==== ======================================== ===================================================== b) Position/status PCA of Ms S Jackson (SVP, Global Communications & CEO Office) ==== ======================================== ===================================================== c) Initial notification/ Initial notification amendment ==== ======================================== ===================================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== =============================================================================================== a) Name GlaxoSmithKline plc ==== ======================================== ===================================================== b) LEI 5493000HZTVUYLO1D793 ==== ======================================== ===================================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== =============================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 ==== ======================================== ===================================================== b) Nature of the The number of Ordinary Shares vesting on transaction awards granted in 2017 under the Company's 2017 Performance Share Plan. ==== ======================================== ===================================================== c) Price(s) and Price(s) Volume(s) volume(s) ==== ======================================== ======================= ========================= GBP0.00 2,363 ===================================================================== ========================= d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ================================================================== ================================ e) Date of the transaction 2020-02-17 ==== ======================================== ===================================================== f) Place of the N/A transaction ==== ======================================== ===================================================== 1. Details of PDMR/person closely associated with them ('PCA') ==== ============================================================================================ a) Name Mr B McNamara ==== ======================================== ================================================== b) Position/status CEO, GSK Consumer Healthcare ==== ======================================== ================================================== c) Initial notification/ Initial notification amendment ==== ======================================== ================================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== ============================================================================================ a) Name GlaxoSmithKline plc ==== ======================================== ================================================== b) LEI 5493000HZTVUYLO1D793 ==== ======================================== ================================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== ============================================================================================ a) Description of American Depositary Shares ('ADSs') the financial instrument ISIN: US37733W1053 ==== ======================================== ================================================== b) Nature of the The number of ADSs vesting on awards granted transaction in 2017 under the Company's 2017 Performance Share Plan. ==== ======================================== ================================================== c) Price(s) and Price(s) Volume(s) volume(s) ==== ======================================== ===================== ======================== $0.00 64,736 ===================== ======================== d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ========================================= ====================================================== e) Date of the transaction 2020-02-18 ==== ======================================== ================================================== f) Place of the N/A transaction ==== ======================================== ================================================== 1. Details of PDMR/person closely associated with them ('PCA') ==== =========================================================================================== a) Name Mr L Miels ==== ======================================== ================================================= b) Position/status President, Global Pharmaceuticals ==== ======================================== ================================================= c) Initial notification/ Initial notification amendment ==== ======================================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== =========================================================================================== a) Name GlaxoSmithKline plc ==== ======================================== ================================================= b) LEI 5493000HZTVUYLO1D793 ==== ======================================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== =========================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 ==== ======================================== ================================================= b) Nature of the The number of Ordinary Shares vesting on transaction awards granted in 2017 under the Company's 2017 Performance Share Plan. ==== ======================================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ==== ======================================== ===================== ======================= GBP0.00 270,447 =================================================================== ======================= d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ================================================================ ============================== e) Date of the transaction 2020-02-17 ==== ======================================== ================================================= f) Place of the N/A transaction ==== ======================================== ================================================= 1. Details of PDMR/person closely associated with them ('PCA') ==== =========================================================================================== a) Name Mr D Redfern ==== ======================================== ================================================= b) Position/status Chief Strategy Officer ==== ======================================== =================================================
c) Initial notification/ Initial notification amendment ==== ======================================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== =========================================================================================== a) Name GlaxoSmithKline plc ==== ======================================== ================================================= b) LEI 5493000HZTVUYLO1D793 ==== ======================================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== =========================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 ==== ======================================== ================================================= b) Nature of the The number of Ordinary Shares vesting on transaction awards granted in 2017 under the Company's 2017 Performance Share Plan. ==== ======================================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ==== ======================================== ===================== ======================= GBP0.00 66,645 =================================================================== ======================= d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ================================================================ ============================== e) Date of the transaction 2020-02-17 ==== ======================================== ================================================= f) Place of the N/A transaction ==== ======================================== ================================================= 1. Details of PDMR/person closely associated with them ('PCA') ==== =========================================================================================== a) Name Mr R Simard ==== ======================================== ================================================= b) Position/status President, Pharmaceuticals Supply Chain ==== ======================================== ================================================= c) Initial notification/ Initial notification amendment ==== ======================================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== =========================================================================================== a) Name GlaxoSmithKline plc ==== ======================================== ================================================= b) LEI 5493000HZTVUYLO1D793 ==== ======================================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== =========================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 ==== ======================================== ================================================= b) Nature of the The number of Ordinary Shares vesting on transaction awards granted in 2017 under the Company's 2017 Performance Share Plan. ==== ======================================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ==== ======================================== ===================== ======================= GBP0.00 9,168 =================================================================== ======================= d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ================================================================ ============================== e) Date of the transaction 2020-02-17 ==== ======================================== ================================================= f) Place of the N/A transaction ==== ======================================== ================================================= 1. Details of PDMR/person closely associated with them ('PCA') ==== =========================================================================================== a) Name Mr P Thomson ==== ======================================== ================================================= b) Position/status President, Global Affairs ==== ======================================== ================================================= c) Initial notification/ Initial notification amendment ==== ======================================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== =========================================================================================== a) Name GlaxoSmithKline plc ==== ======================================== ================================================= b) LEI 5493000HZTVUYLO1D793 ==== ======================================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== =========================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 ==== ======================================== ================================================= b) Nature of the The number of Ordinary Shares vesting on transaction awards granted in 2017 under the Company's 2017 Performance Share Plan. ==== ======================================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ==== ======================================== ===================== ======================= GBP0.00 46,063 =================================================================== ======================= d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ================================================================ ============================== e) Date of the transaction 2020-02-17 ==== ======================================== ================================================= f) Place of the N/A transaction ==== ======================================== ================================================= 1. Details of PDMR/person closely associated with them ('PCA') ==== =========================================================================================== a) Name Ms D Waterhouse ==== ======================================== ================================================= b) Position/status CEO, ViiV Healthcare ==== ======================================== ================================================= c) Initial notification/ Initial notification amendment ==== ======================================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== =========================================================================================== a) Name GlaxoSmithKline plc
==== ======================================== ================================================= b) LEI 5493000HZTVUYLO1D793 ==== ======================================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== =========================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 ==== ======================================== ================================================= b) Nature of the The number of Ordinary Shares vesting on transaction awards granted in 2017 under the Company's 2017 Performance Share Plan. ==== ======================================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ==== ======================================== ===================== ======================= GBP0.00 12,572 =================================================================== ======================= d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ================================================================ ============================== e) Date of the transaction 2020-02-17 ==== ======================================== ================================================= f) Place of the N/A transaction ==== ======================================== ================================================= 1. Details of PDMR/person closely associated with them ('PCA') ==== =========================================================================================== a) Name Ms V Whyte ==== ======================================== ================================================= b) Position/status Company Secretary ==== ======================================== ================================================= c) Initial notification/ Initial notification amendment ==== ======================================== ================================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ==== =========================================================================================== a) Name GlaxoSmithKline plc ==== ======================================== ================================================= b) LEI 5493000HZTVUYLO1D793 ==== ======================================== ================================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted ==== =========================================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 ==== ======================================== ================================================= b) Nature of the The number of Ordinary Shares vesting on transaction awards granted in 2017 under the Company's 2017 Performance Share Plan. ==== ======================================== ================================================= c) Price(s) and Price(s) Volume(s) volume(s) ==== ======================================== ===================== ======================= GBP0.00 9,168 =================================================================== ======================= d) Aggregated information N/A (single transaction) ==== Aggregated volume Price ================================================================ ============================== e) Date of the transaction 2020-02-17 ==== ======================================== ================================================= f) Place of the N/A transaction ==== ======================================== =================================================
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHQKLFFBLLXBBF
(END) Dow Jones Newswires
February 19, 2020 11:35 ET (16:35 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions